Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts. Show more

Location: 80 Guest Street, Boston, MA, 02135, United States | Website: https://www.compasstherapeutics.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

461.9M

52 Wk Range

$1.14 - $4.08

Previous Close

$3.34

Open

$3.46

Volume

1,991,899

Day Range

$3.04 - $3.47

Enterprise Value

370.8M

Cash

100.9M

Avg Qtr Burn

-11.31M

Insider Ownership

14.16%

Institutional Own.

67.42%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tovecimig (CTX-009) (DLL4 and VEGF-A bispecific antibody) Details Biliary Tract Cancer Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX-471 +/- KEYTRUDA® (pembrolizumab) Details Cancer, Small cell lung cancer, Non-small cell lung carcinoma, Melanoma	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tovecimig (CTX-009) (DLL4 and VEGF-A bispecific antibody) Details Cancer, Colorectal cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX-8371 Details Cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX-10726 (PD-1 x VEGF-A bispecific antibody) Details Solid tumor/s	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.